

Robert Weinkove

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8926475/publications.pdf>

Version: 2024-02-01

61
papers

2,287
citations

304368

22
h-index

223531

46
g-index

62
all docs

62
docs citations

62
times ranked

3134
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 304-314. | 0.6 | 8 |
| 2 | Human induced-T-to-natural killer cells have potent anti-tumour activities. <i>Biomarker Research</i> , 2022, 10, 13. | 2.8 | 4 |
| 3 | Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 676-683. | 0.6 | 1 |
| 4 | Glycolipid-peptide conjugate vaccines elicit CD8 ⁺ T cell responses and prevent breast cancer metastasis. <i>Clinical and Translational Immunology</i> , 2022, 11, . | 1.7 | 12 |
| 5 | IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. <i>Leukemia</i> , 2021, 35, 1380-1391. | 3.3 | 26 |
| 6 | An empirical test of the biodiversity hypothesis: Exposure to plant diversity is associated with a reduced risk of childhood acute lymphoblastic leukemia. <i>Science of the Total Environment</i> , 2021, 768, 144627. | 3.9 | 11 |
| 7 | A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat <i>versus</i> low-dose ara-C in older patients with acute myeloid leukaemia: results of the LIQ1 trial. <i>British Journal of Haematology</i> , 2021, 194, 298-308. | 1.2 | 6 |
| 8 | COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768. | 0.5 | 12 |
| 9 | Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 748741. | 2.2 | 7 |
| 10 | T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells. , 2021, 9, e003065. | | 30 |
| 11 | Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities. <i>New Zealand Medical Journal</i> , 2021, 134, 96-108. | 0.5 | 0 |
| 12 | Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1188-1200. | 5.1 | 208 |
| 13 | Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 667-679. | 0.5 | 37 |
| 14 | Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020, 212, 481-489. | 0.8 | 107 |
| 15 | Chimeric antigen receptor T cell therapies: Optimising the dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1678-1689. | 1.1 | 25 |
| 16 | Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. <i>British Journal of Haematology</i> , 2020, 189, 279-290. | 1.2 | 56 |
| 17 | B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib. <i>Pathology</i> , 2020, 52, 491-492. | 0.3 | 2 |
| 18 | Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). <i>BMJ Open</i> , 2020, 10, e034629. | 0.8 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma. <i>Immunotherapy</i> , 2020, 12, 395-406. | 1.0 | 10 |
| 20 | Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey. <i>Internal Medicine Journal</i> , 2019, 49, 358-363. | 0.5 | 9 |
| 21 | FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. <i>Hematological Oncology</i> , 2019, 37, 82-84. | 0.8 | 0 |
| 22 | Maintaining a fit Tâ€cell compartment: lymphoma treatment sequencing in the era of chimeric antigen receptor Tâ€cell therapies. <i>Internal Medicine Journal</i> , 2019, 49, 1338-1338. | 0.5 | 1 |
| 23 | A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 1540-1547. | 0.6 | 3 |
| 24 | Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 1225-1237. | 1.5 | 10 |
| 25 | Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2019, 380, 2225-2236. | 13.9 | 599 |
| 26 | Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. <i>Clinical and Translational Immunology</i> , 2019, 8, e1049. | 1.7 | 205 |
| 27 | THIRD GENERATION CAR T-CELL THERAPY UTILISING TOLL LIKE RECEPTOR 2 CO-STIMULATION. <i>Hematological Oncology</i> , 2019, 37, 517-517. | 0.8 | 0 |
| 28 | Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. <i>Blood</i> , 2019, 134, 2926-2926. | 0.6 | 5 |
| 29 | Abstract B103: Altering the mevalonate pathway to enhance CD8+ T-cell responses. , 2019, , . | | 0 |
| 30 | PB1892 REAL WORLD TREATMENT PERSISTENCE OF NEW ZEALAND IBRUTINIB CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS IN A NAMED PATIENT PROGRAM. <i>HemaSphere</i> , 2019, 3, 861-862. | 1.2 | 1 |
| 31 | A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and Î±-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 285-298. | 2.0 | 49 |
| 32 | Flow Cytometric Analysis of Mechanically Disaggregated Bone Marrow Trepine Biopsies. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 935-940. | 0.7 | 3 |
| 33 | Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. <i>Blood</i> , 2018, 132, 459-459. | 0.6 | 6 |
| 34 | Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials. <i>Internal Medicine Journal</i> , 2017, 47, 695-698. | 0.5 | 18 |
| 35 | Venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 2702-2705. | 0.6 | 108 |
| 36 | Engaging Natural Killer T Cells as â€Universal Helpersâ€™ for Vaccination. <i>Drugs</i> , 2017, 77, 1-15. | 4.9 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins. <i>Scientific Reports</i> , 2017, 7, 14273. | 1.6 | 24 |
| 38 | Temporal changes in neutropenic blood culture isolates and disease associations: a single centre series of 1139 episodes. <i>Internal Medicine Journal</i> , 2017, 47, 962-965. | 0.5 | 1 |
| 39 | Innate-like T cell profile in myeloma: Severe deficiency of V α 2 T cells in aminobisphosphonate-treated patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 977-980. | 0.6 | 6 |
| 40 | Immunity without innate lymphoid cells. <i>Nature Immunology</i> , 2016, 17, 1237-1238. | 7.0 | 6 |
| 41 | Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). <i>Blood</i> , 2016, 128, 2054-2054. | 0.6 | 8 |
| 42 | Non-Invasive Detection of Anaemia Using Digital Photographs of the Conjunctiva. <i>PLoS ONE</i> , 2016, 11, e0153286. | 1.1 | 70 |
| 43 | An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia. <i>Oncolmmunology</i> , 2015, 4, e995568. | 2.1 | 1 |
| 44 | NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity. <i>Chemical Science</i> , 2015, 6, 5120-5127. | 3.7 | 64 |
| 45 | Association between early peak temperature and mortality in neutropenic sepsis. <i>Annals of Hematology</i> , 2015, 94, 857-864. | 0.8 | 10 |
| 46 | Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. <i>Blood</i> , 2015, 126, 496-496. | 0.6 | 17 |
| 47 | Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1283-1297. | 0.5 | 108 |
| 48 | An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment. <i>Blood</i> , 2014, 124, 2953-2963. | 0.6 | 24 |
| 49 | Efficient depletion of chronic lymphocytic leukemia B cells using serial rounds of immunomagnetic depletion. <i>Journal of Immunological Methods</i> , 2013, 396, 152-156. | 0.6 | 0 |
| 50 | Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults. <i>Internal Medicine Journal</i> , 2013, 43, 1151-1154. | 0.5 | 9 |
| 51 | Fever and pancytopenia in a patient with Crohn's disease. <i>Gut</i> , 2013, 62, 1327-1327. | 6.1 | 3 |
| 52 | Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy. <i>Haematologica</i> , 2013, 98, 376-384. | 1.7 | 32 |
| 53 | Temperature management in haematology patients with febrile neutropenia: a practice survey. <i>New Zealand Medical Journal</i> , 2013, 126, 62-73. | 0.5 | 3 |
| 54 | Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma. <i>Clinical Cancer Research</i> , 2012, 18, 6446-6459. | 3.2 | 47 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Species-specific Activity of Glycolipid Ligands for Invariant NKT Cells. <i>ChemBioChem</i> , 2012, 13, 1349-1356. | 1.3 | 25 |
| 56 | Invariant natural killer T cells and asthma: Immunologic reality or methodologic artifact?. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 882-885. | 1.5 | 17 |
| 57 | Fibrinogen concentrate for acquired hypofibrinogaemic states. <i>Transfusion Medicine</i> , 2008, 18, 151-157. | 0.5 | 103 |
| 58 | Low-dose thalidomide in myelofibrosis. <i>Haematologica</i> , 2008, 93, 1100-1101. | 1.7 | 35 |
| 59 | Anticoagulants: current and future therapeutic options. , 2008, , 65-90. | | 0 |
| 60 | Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy. <i>Aids</i> , 2005, 19, 2046-2047. | 1.0 | 7 |
| 61 | Techniques for predicting a favourable response to renal angioplasty in patients with renovascular disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 799-805. | 1.0 | 32 |